Glenn Mattes has more than 30 years of healthcare enterprise leadership and executive experience. He has served in executive capacities in large pharmaceutical companies, biotech and device focused companies in both public and private domains.

Most recently, Glenn was CEO at TFF, Inc., a pharmaceutical company developing a novel inhalation therapy technology platform with an IPO in 2023. Glenn has been involved at a number of development stage companies as CEO and Board level.

Glenn’s specific company experience includes Johnson & Johnson, Rhône Poulenc Rorer, ConvaTec, Candel, Centocor, TFF, Arno Therapeutics, Translational Sciences, The Gores Group, and the Clayton Foundation for Research.

Glenn was appointed to the President’s Advisory Committee on HIV/AIDS by President George W. Bush and the U.S. Secretary of Health and Human Services.